TY - JOUR
T1 - Direct Quantitative Immunochemical Analysis of Autoinducer Peptide IV for Diagnosing and Stratifying Staphylococcus aureus Infections
AU - Montagut, Enrique J.
AU - Acosta, Gerardo
AU - Albericio, Fernando
AU - Royo, Miriam
AU - Godoy-Tena, Gerard
AU - Lacoma, Alicia
AU - Prat, Cristina
AU - Salvador, Juan Pablo
AU - Marco, María Pilar
N1 - Funding Information:
This work has been funded (SAF2015-67476-R, RTI2018-096278-B-C21, both to M.-P. Marco) by MICIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, and to C. Prat through the Instituto de Salud Carlos III (PI17/01139). M.-P. Marco has also received funding from the Fundació Marató de TV3 (TV32018-201825-30-31). Enrique-J. Montagut wishes to thank the FPI fellowship (BES-2016-076496) from the MICIN/AEI/10.13039/501100011033 and ESF investing in your future. We also thank the denomination of consolidated group from the Generalitat de Catalunya: 2017 SGR 1441 (M.-P. Marco) and 2017 SGR 1439 (M. Royo). CIBER Actions, CB06/01/0036 (M.-P. Marco), CB06/06/0031 (C. Prats) and CB06/01/0074 (M. Royo) have been financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund (ERDF). The U2 (Custom Antibody Service (CAbS) and the U3 (Synthesis of Peptide Unit) of the ICTS “NANBIOSIS” at the IQAC-CSIC, are acknowledged for the assistance and support related respectively to the development of the immunoreagents and the synthesis of the different peptide haptens used in this work.
Funding Information:
This work has been funded (SAF2015-67476-R, RTI2018-096278-B-C21, both to M.-P. Marco) by MICIN/AEI/10.13039/501100011033 and by ?ERDF A way of making Europe?, and to C. Prat through the Instituto de Salud Carlos III (PI17/01139). M.-P. Marco has also received funding from the Fundacio? Marato? de TV3 (TV32018-201825-30-31). Enrique-J. Montagut wishes to thank the FPI fellowship (BES-2016-076496) from the MICIN/AEI/10.13039/501100011033 and ESF investing in your future. We also thank the denomination of consolidated group from the Generalitat de Catalunya: 2017 SGR 1441 (M.-P. Marco) and 2017 SGR 1439 (M. Royo). CIBER Actions, CB06/01/0036 (M.-P. Marco), CB06/06/0031 (C. Prats) and CB06/01/0074 (M. Royo) have been financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund (ERDF). The U2 (Custom Antibody Service (CAbS) and the U3 (Synthesis of Peptide Unit) of the ICTS ?NANBIOSIS? at the IQAC-CSIC, are acknowledged for the assistance and support related respectively to the development of the immunoreagents and the synthesis of the different peptide haptens used in this work.
Publisher Copyright:
© 2022 The Authors. Published by American Chemical Society
PY - 2022/3/11
Y1 - 2022/3/11
N2 - An immunochemical strategy to detect and quantify AIP-IV, the quorum sensing (QS) signaling molecule produced by Staphylococcus aureus agr type IV, is reported here for the first time. Theoretical calculations and molecular modeling studies have assisted on the design and synthesis of a suitable peptide hapten (AIPIVS), allowing to obtain high avidity and specific antibodies toward this peptide despite its low molecular weight. The ELISA developed achieves an IC50 value of 2.80 ± 0.17 and an LOD of 0.19 ± 0.06 nM in complex media such as 1/2 Tryptic Soy Broth. Recognition of other S. aureus AIPs (I-III) is negligible (cross-reactivity below 0.001%), regardless of the structural similarities. A pilot study with a set of clinical isolates from patients with airways infection or colonization demonstrates the potential of this ELISA to perform biomedical investigations related to the role of QS in pathogenesis and the association between dysfunctional agr or the agr type with unfavorable clinical outcomes. The AIP-IV levels could be quantified in the low nanomolar range in less than 1 h after inoculating agr IV-genotyped isolates in the culture broth, while those genotyped as I-III did not show any immunoreactivity after a 48 h growth, pointing to the possibility to use this technology for phenotyping S. aureus. The research strategy here reported can be extended to the rest of the AIP types of S. aureus, allowing the development of powerful multiplexed chips or point-of-care (PoC) diagnostic devices to unequivocally identify its presence and its agr type on samples from infected patients.
AB - An immunochemical strategy to detect and quantify AIP-IV, the quorum sensing (QS) signaling molecule produced by Staphylococcus aureus agr type IV, is reported here for the first time. Theoretical calculations and molecular modeling studies have assisted on the design and synthesis of a suitable peptide hapten (AIPIVS), allowing to obtain high avidity and specific antibodies toward this peptide despite its low molecular weight. The ELISA developed achieves an IC50 value of 2.80 ± 0.17 and an LOD of 0.19 ± 0.06 nM in complex media such as 1/2 Tryptic Soy Broth. Recognition of other S. aureus AIPs (I-III) is negligible (cross-reactivity below 0.001%), regardless of the structural similarities. A pilot study with a set of clinical isolates from patients with airways infection or colonization demonstrates the potential of this ELISA to perform biomedical investigations related to the role of QS in pathogenesis and the association between dysfunctional agr or the agr type with unfavorable clinical outcomes. The AIP-IV levels could be quantified in the low nanomolar range in less than 1 h after inoculating agr IV-genotyped isolates in the culture broth, while those genotyped as I-III did not show any immunoreactivity after a 48 h growth, pointing to the possibility to use this technology for phenotyping S. aureus. The research strategy here reported can be extended to the rest of the AIP types of S. aureus, allowing the development of powerful multiplexed chips or point-of-care (PoC) diagnostic devices to unequivocally identify its presence and its agr type on samples from infected patients.
KW - agr group
KW - antibodies
KW - autoinducer peptides
KW - diagnostic
KW - quorum sensing
KW - Staphylococcus aureus
UR - http://www.scopus.com/inward/record.url?scp=85125388503&partnerID=8YFLogxK
U2 - 10.1021/acsinfecdis.1c00670
DO - 10.1021/acsinfecdis.1c00670
M3 - Article
C2 - 35175740
AN - SCOPUS:85125388503
SN - 2373-8227
VL - 8
SP - 645
EP - 656
JO - ACS Infectious Diseases
JF - ACS Infectious Diseases
IS - 3
ER -